EDAP Reports First Quarter 2020 Results and Provides Operational Update
EDAP Reports First Quarter 2020 Results and Provides Operational Update
- Maintains strong balance sheet with
EUR 18.5 million (USD 20.3 million ) in cash as ofMarch 31, 2020 - Signs exclusive worldwide distribution agreement with Exact Imaging to combine their innovative micro-ultrasound technology with Focal One to offer an end-to-end focal therapy solution for the diagnosis and management of prostate cancer
- Announces strategic refocusing of future development programs towards high intensity focused ultrasound (HIFU) and related growth opportunities
- Company to host a conference call tomorrow,
May 14 at8:30 am EDT
“Regarding our first quarter results, we expected and did experience a deceleration in both procedure volumes and new system sales as hospitals around the world worked to fight the COVID-19 pandemic. However, we are seeing early signs that certain markets are returning to a more normalized business environment, an indication that prostate cancer procedures that had been previously delayed will now resume. As far as system sales, Focal One represents a significant capital outlay for a hospital and as a result, hospitals have been postponing significant technology investments during the COVID outbreak. We strongly believe that many of these sales will ultimately be completed this year. In the meantime, we have continued to grow our pipeline of projects and leads during the worst of the pandemic.
“After an extensive review of our different businesses, including HIFU, Distribution and ESWL, we have decided to strengthen and refocus our development efforts towards HIFU for both prostate applications and beyond. As a part of this initiative, we will be revisiting our lithotripsy R&D investment strategy (to include discontinuation of Endo-UP platform). Based on recent trends, we believe it is important to shift and narrow our R&D focus and marketing towards HIFU and Distribution, as these have shown strong growth and have the potential for future growth and contribution. Importantly, our Lithotripsy business generates significant and steady cash flow for the company that can finance future HIFU development, and we intend to sustain this cash flow by continuing to sell and support our state of the art Sonolith range of devices. But given the opportunities in HIFU that are in front of us, and our technology leadership position, we believe now is the right time to pivot more fully toward that business and to accelerate HIFU expansion,”
First Quarter 2020 Results
Total revenue for the first quarter 2020 was
Total revenue in the HIFU business for the first quarter 2020 was
For the three months ended
Gross profit for the first quarter 2020 was
Operating expenses were
Operating loss for the first quarter of 2020 was
Net loss for the first quarter of 2020 was
As of
Conference Call
An accompanying conference call and webcast will be conducted by management to review the results. The call will be held at 8:30am EDT on Thursday, May 14, 2020. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Call & Webcast
Domestic: 877-451-6152
International: 201-389-0879
Passcode: 13703225
Webcast: http://public.viavid.com/index.php?id=139678
Following the live call, a replay will be available on the Company's website, www.edap-tms.com under "Investors Information."
About
A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy devices, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the
Company Contact
Investor Relations / Legal Affairs
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
212-915-2568
jeremy@lifesciadvisors.com
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of Euros and
Three Months Ended: | Three Months Ended: | ||||||
2020 Euros |
|
2019 Euros |
2020 $US |
2019 $US |
|||
Sales of medical equipment |
4,125 1,255 |
6,546 1,371 |
4,551 1,385 |
7,432 1,556 |
|||
Sales of spare parts, supplies and Services |
2,228 |
2,215 |
2,458 |
2,515 |
|||
TOTAL |
7,608 | 10,131 | 8,394 | 11,503 | |||
Other revenues | 2 | - | 2 | - | |||
TOTAL REVENUES | 7,610 | 10,131 | 8,295 | 11,503 | |||
Cost of sales | (4,548) | (5,266) | (5,018) | (5,979) | |||
GROSS PROFIT | 3,062 | 4,865 | 3,378 | 5,523 | |||
Research & development expenses | (1,042) | (1,013) | (1,150) | (1,150) | |||
S, G & A expenses | (3,480) | (3,644) | (3,839) | (4,137) | |||
Total operating expenses | (4,522) | (4.657) | (4,989) | (5,287) | |||
OPERATING PROFIT (LOSS) | (1,460) | 208 | (1,611) | 236 | |||
Interest (expense) income, net | (20) | (31) | (22) | (35) | |||
Currency exchange gains (loss), net | 289 | 265 | 319 | 301 | |||
INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST | (1,191) | 443 | (1,315) | 503 | |||
Income tax (expense) credit | (116) | (115) | (128) | (131) | |||
NET INCOME (LOSS) |
(1,308) | 328 | (1,443) | 372 |
|||
Earning per share – Basic | (0.04) | 0.01 | (0.05) | 0.01 | |||
Average number of shares used in computation of EPS | 29,141,566 | 28,997,866 | 29,141,566 | 28,997,866 | |||
Earning per share – Diluted | (0.04) | 0.01 | (0.05) | 0.01 | |||
Average number of shares used in computation of EPS for positive net income |
29,141,566 | 29,656,133 | 29,141,566 | 29,656,133 |
NOTE: Translated for convenience of the reader to
UNAUDITED CONSOLIDATED BALANCE SHEETS HIGHLIGHTS
(Amounts in thousands of Euros and
2020 Euros |
2019 Euros |
2020 $US |
2019 $US |
||||
Cash, cash equivalents and short-term investments | 18,450 | 20,886 | 20,323 | 23,449 | |||
Total current assets | 39,188 | 42,097 | 43,168 | 47,263 | |||
Total current liabilities | 16,664 | 17,493 | 18,356 | 19,640 | |||
Shareholders’ Equity | 25,896 | 27,359 | 28,526 | 30,716 |
NOTE: Translated for convenience of the reader to
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
THREE MONTHS ENDED
(Amounts in thousands of Euros)
HIFU Division |
UDS Division |
Reconciling Items |
Total After Consolidation |
||||||
Sales of goods |
578 |
3,547 |
4,125 |
||||||
Sales of RPPs & Leases | 924 | 331 | 1,255 | ||||||
Sales of spare parts & services | 421 | 1,808 | 2,228 | ||||||
TOTAL |
1,922 | 5,686 | 7,608 | ||||||
Other revenues |
2 | - | 2 | ||||||
TOTAL REVENUES | 1,924 | 5,686 | 7,610 | ||||||
GROSS PROFIT (% of Total Revenues) |
783 | 40.7% | 2,279 | 40.1% | 3,062 | 40.2% | |||
Research & Development | (543) | (499) | (1,042) | ||||||
Total SG&A plus depreciation | (1,262) | (1,820) | (397) | (3,479) | |||||
OPERATING PROFIT (LOSS) |
(1,023) |
(39) |
(397) |
(1,460) |
Attachment
Source: EDAP TMS S.A.